USA - New York Stock Exchange - NYSE:HIMS - US4330001060 - Common Stock
The current stock price of HIMS is 33.41 USD. In the past month the price decreased by -9.87%. In the past year, price increased by 25.46%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.7 | 101.72B | ||
| CI | THE CIGNA GROUP | 9.82 | 74.56B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 126.79 | 23.32B | ||
| LH | LABCORP HOLDINGS INC | 15.91 | 20.86B | ||
| DGX | QUEST DIAGNOSTICS INC | 17.81 | 19.33B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.11B | ||
| DVA | DAVITA INC | 12.41 | 8.08B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 37.65 | 6.93B | ||
| CHE | CHEMED CORP | 19.26 | 6.00B | ||
| RDNT | RADNET INC | 186.71 | 5.47B | ||
| OPCH | OPTION CARE HEALTH INC | 21.64 | 5.12B | ||
| BLLN | BILLIONTOONE INC CL A | N/A | 4.05B |
Hims & Hers Health, Inc. operates a telehealth consultation platform. The company is headquartered in San Francisco, California and currently employs 1,637 full-time employees. The company went IPO on 2019-09-09. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. The company connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. The company also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
HIMS & HERS HEALTH INC
2269 Chestnut St, #523
San Francisco CALIFORNIA 94123 US
CEO: Andrew Dudum
Employees: 1637
Phone: 14158510195
Hims & Hers Health, Inc. operates a telehealth consultation platform. The company is headquartered in San Francisco, California and currently employs 1,637 full-time employees. The company went IPO on 2019-09-09. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. The company connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. The company also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
The current stock price of HIMS is 33.41 USD. The price increased by 2.89% in the last trading session.
HIMS does not pay a dividend.
HIMS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for HIMS & HERS HEALTH INC (HIMS) is 61.87. This is based on the reported non-GAAP earnings per share of 0.54 and the current share price of 33.41 USD.
HIMS & HERS HEALTH INC (HIMS) will report earnings on 2026-02-23, after the market close.
ChartMill assigns a fundamental rating of 5 / 10 to HIMS. HIMS has an average financial health and profitability rating.
Over the last trailing twelve months HIMS reported a non-GAAP Earnings per Share(EPS) of 0.54. The EPS increased by 22.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.05% | ||
| ROA | 5.99% | ||
| ROE | 23.03% | ||
| Debt/Equity | 1.67 |
21 analysts have analysed HIMS and the average price target is 46.4 USD. This implies a price increase of 38.87% is expected in the next year compared to the current price of 33.41.
For the next year, analysts expect an EPS growth of -12.6% and a revenue growth 60.27% for HIMS